Retrospective Cohort Study
Copyright ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jun 21, 2020; 26(23): 3249-3259
Published online Jun 21, 2020. doi: 10.3748/wjg.v26.i23.3249
Medications in type-2 diabetics and their association with liver fibrosis
Mohamed Tausif Siddiqui, Hina Amin, Rajat Garg, Pravallika Chadalavada, Wael Al-Yaman, Rocio Lopez, Amandeep Singh
Mohamed Tausif Siddiqui, Hina Amin, Wael Al-Yaman, Amandeep Singh, Department of Gastroenterology, Hepatology and Nutrition, Digestive Diseases and Surgery Institute, Cleveland Clinic, Cleveland, OH 44195, United States
Rajat Garg, Pravallika Chadalavada, Department of Hospital Medicine, Cleveland Clinic, OH 44195, United States
Rocio Lopez, Department of Quantitative Health Sciences, Cleveland Clinic, OH 44195, United States
Author contributions: Siddiqui MT, Amin H, Al-Yaman W and Singh A were involved in conceptualization, data curation, and project administration; Siddiqui MT, Amin H, Al-Yaman W, Singh A, Chadalvada P and Garg R were involved in writing; Lopez R performed the statistical analysis; all authors were involved in interpretation of the results, reviewing and editing of the draft.
Institutional review board statement: The study was reviewed and approved for publication by our Institutional Reviewer.
Informed consent statement: This was a retrospective study which involved the chart review. Requirement for individual patient consent was waived by the IRB.
Conflict-of-interest statement: All the Authors have no conflict of interest related to the manuscript.
Data sharing statement: The original anonymous dataset is available on request from the corresponding author at singha4@ccf.org.
STROBE statement: The guidelines of the STROBE Statement have been adopted and implemented.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Amandeep Singh, MD, Attending Doctor, Staff Physician, Department of Gastroenterology, Hepatology and Nutrition, Digestive Diseases and Surgery Institute, Cleveland Clinic, 9500 Euclid Ave Suite-A5, Cleveland, OH 44195, United States. singha4@ccf.org
Received: January 31, 2020
Peer-review started: January 31, 2020
First decision: February 27, 2020
Revised: June 6, 2020
Accepted: June 10, 2020
Article in press: June 10, 2020
Published online: June 21, 2020
ARTICLE HIGHLIGHTS
Research background

The prevalence of nonalcoholic fatty liver disease (NAFLD) is estimated around 25% of the global population and is expected to increase further in the coming years. Type-2 diabetes mellitus is a major risk factor for NAFLD with significant portion of diabetic patients develop progressive liver disease and a proportion of these patients also develop advanced fibrosis (AF). NAFLD pose significant health care burden and is associated with significant mortality and morbidity.

Research motivation

Patients with diabetes are commonly on multiple medication regimen, of which, some have a positive impact on slowing the progression of NAFLD to AF. For instance, HMG-CoA reductase inhibitors (statins) and Angiotensin converting enzyme inhibitors have been shown previously to be associated with reduction in AF in viral hepatitis patients. There is a paucity of data on the association of these medications on the progression of liver fibrosis in NAFLD patients.

Research objectives

We aimed to understand the association of the different pharmacologic modalities used in the treatment of diabetes mellitus on the progression of liver fibrosis in NAFLD patients with type-2 diabetes.

Research methods

We identified all adult patients with type-2 diabetes mellitus who underwent liver biopsy for suspected NAFLD at the Cleveland Clinic between January 1, 2000 to December 31, 2015. We retrospectively reviewed a cohort of 1183 patients with type-2 diabetes and biopsy proven NAFLD. We compared demographics, clinical characteristics, and differences in pattern of medication use in patients who had biopsy-proven NAFLD with and without advance fibrosis. A univariate and multivariate analysis was performed to assess the association of different classes of medication with and without the presence of AF.

Research results

We found that the patients who were receiving Metformin, Liraglutide, Lisinopril, Hydrochlorothiazide, Atorvastatin and Simvastatin were less likely to have AF on biopsy, while patients who were receiving furosemide and spironolactone were more likely to have AF when they underwent liver biopsy. Diabetic patients with chronic kidney disease were more likely to have AF on liver biopsy.

Research conclusions

Our study highlights the protective role of some of the commonly used medications in the treatment of type-2 diabetes mellitus. We propose that Metformin, Liraglutide, Lisinopril, Hydrochlorothiazide, Atorvastatin and Simvastatin may have a beneficial role in slowing down the progression of NAFLD.

Research perspectives

Although it is possible that some unknown confounding factors could have impacted our findings, this study lays a solid groundwork for future prospective studies to further investigate the protective role of these medications on the progression of liver fibrosis in diabetic patients with NAFLD.